Did you mean cysteine kinase pent para para?
Displaying drugs 1001 - 1025 of 1334 in total
Rabusertib
Rabusertib has been used in trials studying the treatment of Cancer, Solid Tumors, Advanced Cancer, Pancreatic Neoplasms, and Non Small Cell Lung Cancer.
Investigational
Matched Categories: … Protein Kinase Inhibitors …
Pentabromophenol
Experimental
Pilaralisib
Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.
Investigational
Matched Description: … is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase …
Arginine glutamate
Investigational
Cyclohexyl-pentyl-maltoside
Experimental
Avutometinib
Avutometinib (RO-5126766 free base) is under investigation in clinical trial NCT03875820 (Phase I Trial of VS-6063 and RO5126766.).
Investigational
Matched Categories: … Protein Kinase Inhibitors …
Silmitasertib
Silmitasertib is under investigation in clinical trial NCT03904862 (Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery).
Investigational
Matched Categories: … Casein Kinase II, antagonists & inhibitors …
PF-06700841
PF-06700841 is under investigation in clinical trial NCT03236493 (Safety and Pharmacokinetic Study of PF-06700841 in Japanese Healthy Volunteers).
Investigational
Matched Categories: … Protein Kinase Inhibitors …
Sovleplenib
Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting spleen tyrosine kinase (Syk). It is under investigation in clinical trial NCT03483948 (Phase I Study of Hmpl-523+azacitidine in Elderly Patients With Acute Myeloid Leukemia).
Investigational
Matched Description: … investigational, selective small molecule inhibitor for oral administration targeting spleen tyrosine kinase …
EHP-102
Investigational
Dubermatinib
Dubermatinib is under investigation in clinical trial NCT03572634 (Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL).
Investigational
Matched Description: … under investigation in clinical trial NCT03572634 (Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase …
PF-03814735
PF-03814735 has been used in trials studying the treatment of Solid Tumors.
Investigational
Matched Categories: … Protein Kinase Inhibitors …
X-396
X-396 has been used in trials studying the treatment of Advanced Solid Tumors and Non-small Cell Lung Cancer.
Investigational
Matched Categories: … Protein Kinase Inhibitors …
Rivoceranib
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
Investigational
Matched Categories: … Protein Kinase Inhibitors …
Ensartinib
Ensartinib is under investigation in clinical trial NCT03420508 (Treating Patients With Melanoma and ALK Alterations With Ensartinib).
Investigational
Matched Categories: … Protein Kinase Inhibitors …
Rupintrivir
Rupintrivir is a rhinovirus 3C protease inhibitor in development for use against human rhinoviral (HRV) infections. Rupintrivir was active against all 48 HRV serotypes tested in a cell protection assay in H1-HeLa cells. It is designed to combat colds caused by rhinovirus.
Investigational
Matched Iupac: … methyl]-6-methyl-5-[(5-methyl-1,2-oxazol-3-yl)formamido]-4-oxoheptanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pent …
5-PENTYL-2-PHENOXYPHENOL
Experimental
Displaying drugs 1001 - 1025 of 1334 in total